RxDoctor Payments Data

Wayland Lim, MD

Interventional Cardiology · Sacramento, CANPI 1134311905

Payments from drug & device makers

$67,357in general payments, 2019–2025

Across 722 payments — averaging $93.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$46K
  • Boston Scientific$4K
  • Edwards Lifesciences$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Shockwave Medical, Inc$1K
  • Philips North America LLC$956
  • plus $10K from 46 others

What the payments were for

  • Travel & lodging$8,20530%
  • Food & beverage$18,79269%
  • Education$1701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,357 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$488,765
Medicare patients
1,398
Services billed
6,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban395$573,653
Repatha SureclickEvolocumab126$152,217
EntrestoSacubitril/Valsartan75$132,778
XareltoRivaroxaban96$115,965
JardianceEmpagliflozin45$71,026
FarxigaDapagliflozin Propanediol48$47,524
MultaqDronedarone Hcl21$46,992
Praluent PenAlirocumab40$43,409
BrilintaTicagrelor41$37,297
Ezetimibe277$12,806
Atorvastatin Calcium869$10,029
Rosuvastatin Calcium360$8,911
Metoprolol Succinate518$8,501
Ranolazine ErRanolazine55$6,978
Propafenone Hcl ErPropafenone Hcl34$6,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$314$573,653395 claims
NovartisEntresto$552$132,77875 claims
Johnson & JohnsonXarelto$503$115,96596 claims
AstraZenecaFarxiga, Brilinta$415$84,82289 claims
Boehringer IngelheimJardiance$226$71,02645 claims
Sanofi-aventis U.S. LLCMultaq$289$46,99221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →